In a first test, Tolmachev and colleagues70 tested an anti-HER2 Affibody-based peptide nucleic acid with a complementary hybridization probe that showed low kidney uptake and specific high affinity binding on HER2-expressing cells in vitro with substantial tumor uptake in HER2-expressing xenografts in vivo. This evidence concerns the gene ERBB2 and neoplasm.